Integumen PLC Highlands Nat. Resources agreement with Cellulac
02 August 2019 - 4:01PM
RNS Non-Regulatory
TIDMSKIN
Integumen PLC
02 August 2019
AIM share code: SKIN
2 August 2019
Integumen PLC
("Integumen" or "Company")
Integumen notes Highlands agreement with Cellulac plc to supply
hemp-derived CBD for medical grade conversion
Integumen to use Cellulac converted CBD for Its skincare and
Wound pHase wound care products
Integumen is pleased to note Highlands Natural Resources plc's
("Highlands") announcement that it has entered into a two-year
agreement to provide hemp-derived CBD grown under
quality-controlled conditions, with less than 0.2% THC, to Cellulac
plc (9.35% owned by Integumen plc) for conversion to medical grade
CBD. This will then be incorporated into, and tested on, Integumen
plc's CBD infused wound care "Wound pHase" and STOER range of
skincare products.
Under the agreement, Highlands will supply CBD to Cellulac for
the conversion into medical grade CBD, who will then submit the
finished products to Integumen's Labskin test facilities. The CBD
will be infused on to Integumen's WoundpHase and STOER range of
wound care and skin care products, providing a vertically
integrated farm-to-finished product.
Gerard Brandon - CEO of Integumen, comments:
"We are delighted to to be part of this agreement with
Highlands. To satisfy regulatory authorities in multiple
jurisdictions, it is necessary to identify the origin of each plant
and confirm the supervised growth from seed, extraction and
shipment. The CBD market is still evolving, so it is imperative
that any CBD infused treatments in wound care and skin care are
subject to the highest testing standards, scientific verification
and validation prior to product launch."
Robert Price - Executive Chairman and CEO Highlands,
comments:
"With over 110 varieties of hemp, there is a requirement to
provide quality hemp-derived CBD to meet specifications for the
medical, cosmeceutical and pharmaceutical sectors, grown under
supervised quality-controlled conditions. Our state-of-the-art,
33,000-foot indoor hemp growing facility in Colorado, US, offers
the quality and consistency grade needed to meet those requirements
and we welcome the recognition of the quality products and the
opportunity to collaborate with Cellulac and Integumen to deliver
consumer products for wound care and skin care consumer products in
the shortest possible time."
CBD and Pain Relief:
The human body makes its own version of exocannbinoids (THC and
CBD) called endocannabinoids which bind to two receptors CB1 and
CB2. These endocannabinoids operate like neurotransmitters,
switching on and off nerves. These, in turn, spark or dampen the
electric pulses that creates thoughts, behaviours and movements.
Tetrahydrocannabinoil ("THC"), the psychoactive substance that
creates a high feeling, has a strong affinity to CB1, whereas CBD,
with less than 0.2% THC does not typically interact with CB1 but
can trigger a response to the body's endocannabinoids. Researchers,
including Dr Joseph Cheer, a neurobiologist at the University of
Maryland who specialises in cannabinoids, suggest that CBD switches
off electrical pulses associated with pain by tweaking the amount
of calcium that can get inside the body's nerves(1) .
Labskin has already successfully tested CBD demonstrating
anti-microbial and anti-inflammatory effects in skin-care with the
Company's STOER For Men cosmetics products, and is currently
testing CBD infused female hygiene products at the Company's
Labskin test facility in York, UK.
Wound Care Growth:
The incidence of chronic wounds is growing with approximately
1-2% of the USA population sustaining chronic wounds during their
lifetime, leading to approximately 6.5 million incidences at an
annual cost of approximately US$25 billion. In Europe, wound
management costs approximately EUR6650-EUR10,000 per patient and
consumes 2-4% of European healthcare budgets.
Patients with diabetes are also at high risk of wound
infections. Approximately 387 million people have diabetes, and
this number is predicted to increase by 205 million by 2035(2)
.
1.
https://www.pbs.org/newshour/science/is-cbd-legal-heres-what-you-need-to-know-according-to-science
2. https://doi.org/10.1016/j.tibtech.2018.04.004
Contacts
Integumen plc Gerard Brandon, CEO +44 (0) 7340 055 648
SPARK Advisory Partners
Limited Neil Baldwin/Andrew
(Nominated Adviser) Emmott +44 (0) 113 370 8974
--------------------- ---------------------
Turner Pope Investments
(TPI) Limited (Broker) Andy Thacker +44 (0) 20 3621 4120
--------------------- ---------------------
About Integumen:
Integumen is a vertically integrated business, collaborating
their Labskin technology platform with partners in artificial
intelligence, clinical research, medical device and life science.
These collaborators are building their own technology on top of the
Labskin AI backbone. Labskin allows skin-care, health-care,
pharmaceutical manufacturers and cosmetic companies to test their
products on human-like skin in a real-world environment with full
access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic
operational expertise and offers solutions to our clients, from
regulatory approvals, right through to marketing fully tested
ingredients that have been certified on our Laboratory grown living
human tissue.
Notes to Editors:
CBD (Cannabidiol) oil is an extract from the Cannabis Sativa
plant. Hemp-derived CBD is produced from the seeds of the plant and
does not contain the psychoactive ingredient Tetrahydrocannabinol
(THC) or does so only in trace amounts. This differentiates
hemp-derived CBD oil from CBD Oil produced from flowers, leaves and
stalks of the plant (which are higher in THC content). CBD products
which contain less than 0.2% THC concentration are legal in the
UK.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUARBRKAAWRAR
(END) Dow Jones Newswires
August 02, 2019 02:01 ET (06:01 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024